Key Takeaways Expansion in high-margin diabetes and digital pathology products, plus healthcare IT, positions PHC to benefit from digitalization and recurring service revenues. Investment in R&D and operational streamlining enhances competitiveness and resilience against external risks, supporting sustainable future growth.Read more
PHC Holdings Corporation, through its subsidiaries, provides medical devices, healthcare IT solutions, and life science products and services primarily in Japan. The company operates through Diabetes Management, Healthcare Solutions, and Diagnostic & Life Sciences segments. It offers blood glucose monitoring systems, continuous glucose monitoring systems, and diabetes application; patient and record billing software, including electronic medical record system, electronic medication history system, and healthcare note service; and diagnostic testing products, which include clinical testing, diagnostic reagents and instruments, and drug development support products. The company also provides biologic and cell preservation products, comprising low temperature freezers, CO2 incubators, and automatic tablet counting and packaging system; and cancer pathology products, which comprise tissue processor, microscopic slides, and cytology staining solutions. In addition, it develops and produces precision medical devices that help with early detection and ongoing monitoring of diseases, such as diabetes and asthma, and drug delivery systems that support medical treatment. The company was formerly known as Panasonic Healthcare Holdings Co., Ltd. and changed its name to PHC Holdings Corporation in April 2018. PHC Holdings Corporation was founded in 1969 and is headquartered in Tokyo, Japan.
